 Aeterna Zentaris Inc. AEZS AEZS the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of a public offering of 26,666,666 units at a price to the public of 0.45 per unit, for gross proceeds of 12 million, before deducting placement agent fees and other offering expenses payable by the Company. Each unit contains one common share or common share equivalent and one common warrant to purchase one common share. The common shares or common share equivalents and common share warrants included in the units can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. 